• Mutation; HGNC; HGNC:7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (PubMed=22812491).
  

PubMed=22812491; DOI=10.3109/10428194.2012.713481; PMCID=PMC4406272
Chitta K.S., Paulus A., Ailawadhi S., Foster B.A., Moser M.T., Starostik P., Masood A., Sher T., Miller K.C., Iancu D.M., Conroy J., Nowak N.J., Sait S.N.J., Personett D.A., Coleman M., Furman R.R., Martin P., Ansell S.M., Lee K., Chanan-Khan A.A.
Development and characterization of a novel human Waldenstrom macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute -- Waldenstrom Macroglobulinemia 1.
Leuk. Lymphoma 54:387-396(2013)

PubMed=22950966; DOI=10.3109/10428194.2012.727418
Drexler H.G., Chen S., MacLeod R.A.F.
Would the real Waldenstrom cell line please stand up?
Leuk. Lymphoma 54:224-226(2013)

PubMed=25853860; DOI=10.1371/journal.pone.0122338; PMCID=PMC4390194
Paulus A., Chitta K.S., Wallace P.K., Advani P.P., Akhtar S., Blake M.K.K., Ailawadhi S., Chanan-Khan A.A.
Immunophenotyping of Waldenstroms macroglobulinemia cell lines reveals distinct patterns of surface antigen expression: potential biological and therapeutic implications.
PLoS ONE 10:E0122338-E0122338(2015)

PubMed=28548645; DOI=10.1038/bcj.2017.40; PMCID=PMC5518884
Paulus A., Akhtar S., Yousaf H.M., Manna A., Paulus S.M., Bashir Y., Caulfield T.R., Blake M.K.K., Chitta K.S., Wang X., Asmann Y., Hudec R., Springer W., Ailawadhi S., Chanan-Khan A.A.
Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment.
Blood Cancer J. 7:e565.1-e565.11(2017)